IOVANCE BIOTHERAPEUTICS, INC. Quarterly Deferred Income Tax Liabilities, Net in USD from Q2 2023 to Q3 2024

Taxonomy & unit
us-gaap: USD
Description
Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting.
Summary
Iovance Biotherapeutics, Inc. quarterly Deferred Income Tax Liabilities, Net history and growth rate from Q2 2023 to Q3 2024.
  • Iovance Biotherapeutics, Inc. Deferred Income Tax Liabilities, Net for the quarter ending September 30, 2024 was $32.2M, a 75.6% increase year-over-year.
Deferred Income Tax Liabilities, Net, Quarterly (USD)
Deferred Income Tax Liabilities, Net, YoY Quarterly Growth (%)
Period Value YoY Chg Change % Date Report Filed
Q3 2024 $32.2M +$13.9M +75.6% Sep 30, 2024 10-Q 2024-11-07
Q2 2024 $31.9M +$11.7M +57.6% Jun 30, 2024 10-Q 2024-08-08
Q1 2024 $33.3M Mar 31, 2024 10-Q 2024-05-09
Q4 2023 $17.3M Dec 31, 2023 10-Q 2024-11-07
Q3 2023 $18.3M Sep 30, 2023 10-Q 2023-11-07
Q2 2023 $20.2M Jun 30, 2023 10-Q 2023-08-08
* An asterisk sign (*) next to the value indicates that the value is likely invalid.